28147376|t|Solifenacin in the Elderly: Results of an Observational Study Measuring Efficacy, Tolerability and Cognitive Effects
28147376|a|The study aimed to evaluate the efficacy and safety of solifenacin in older patients with overactive bladder (OAB). Observational data on patients aged ≥70 years and the prescribed flexible dose of solifenacin for OAB were collected at 294 offices of German general practitioners. Baseline and week 12 data included type and severity of OAB symptoms, adverse events, quality of life, and change in cognitive function per Mini Mental State Examination (MMSE). Mean age of 774 patients was 78 ± 6 years. A decrease was observed in all OAB symptoms including a reduction of urinary urgency and micturition, each by 4 episodes per 24 h. No change in mean MMSE score s was apparent at week 12. Adverse events and treatment discontinuations were low at 5.8 and 0.5%, respectively. Solifenacin was well-tolerated while OAB symptoms declined at week 12. No relevant effect of solifenacin on cognitive function was observed in this elderly population.
28147376	0	11	Solifenacin	T109,T121	C1099677
28147376	19	26	Elderly	T098	C0001792
28147376	28	35	Results	T033	C2825142
28147376	42	61	Observational Study	T062	C1518527
28147376	72	80	Efficacy	T080	C1280519
28147376	82	94	Tolerability	T080	C1704410
28147376	99	116	Cognitive Effects	T033	C0935657
28147376	121	126	study	T062	C0008972
28147376	149	157	efficacy	T080	C1280519
28147376	162	168	safety	T068	C0036043
28147376	172	183	solifenacin	T109,T121	C1099677
28147376	187	201	older patients	T101	C0030705
28147376	207	225	overactive bladder	T047	C0878773
28147376	227	230	OAB	T047	C0878773
28147376	233	251	Observational data	T078	C1511726
28147376	255	263	patients	T101	C0030705
28147376	287	297	prescribed	T058	C0278329
28147376	298	306	flexible	T080	C0443220
28147376	307	311	dose	T081	C0178602
28147376	315	326	solifenacin	T109,T121	C1099677
28147376	331	334	OAB	T047	C0878773
28147376	357	364	offices	T073,T093	C0031834
28147376	368	374	German	T098	C1556085
28147376	375	396	general practitioners	T097	C0017319
28147376	419	423	data	T078	C1511726
28147376	433	437	type	T080	C0332307
28147376	442	450	severity	T080	C0439793
28147376	454	457	OAB	T047	C0878773
28147376	458	466	symptoms	T184	C1457887
28147376	468	482	adverse events	T046	C0877248
28147376	484	499	quality of life	T078	C0034380
28147376	505	511	change	T169	C0392747
28147376	515	533	cognitive function	T041	C0392335
28147376	538	567	Mini Mental State Examination	T060	C0451306
28147376	569	573	MMSE	T060	C0451306
28147376	576	584	Mean age	T032	C0001779
28147376	592	600	patients	T101	C0030705
28147376	621	629	decrease	T080	C0392756
28147376	650	653	OAB	T047	C0878773
28147376	654	662	symptoms	T184	C1457887
28147376	675	684	reduction	T080	C0392756
28147376	688	703	urinary urgency	T047	C0085606
28147376	708	719	micturition	T040	C0042034
28147376	731	739	episodes	T079	C0332189
28147376	750	759	No change	T033	C0442739
28147376	768	778	MMSE score	T033	C2960235
28147376	797	801	week	T079	C0439230
28147376	806	820	Adverse events	T046	C0877248
28147376	825	851	treatment discontinuations	T058	C0457454
28147376	857	860	low	T081	C1611820
28147376	892	903	Solifenacin	T109,T121	C1099677
28147376	929	932	OAB	T047	C0878773
28147376	933	941	symptoms	T184	C1457887
28147376	963	981	No relevant effect	T080	C1301751
28147376	985	996	solifenacin	T109,T121	C1099677
28147376	1000	1018	cognitive function	T041	C0392335
28147376	1040	1058	elderly population	T098	C0001792